Compare Medtronic PLC (MDT) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Tesla, Inc. — how do they compare? Medtronic PLC trades at $87.75 (market cap $112.24B), while Tesla, Inc. trades at $381.54 (market cap $1.48T). The key difference: Tesla, Inc. is far larger — about 13.2× Medtronic PLC's market cap, and Medtronic PLC pays a 3.28% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Tesla, Inc. for 88 Days on average.
| MDT | TSLA | |
|---|---|---|
Market Cap | $112.24B | $1.48T |
Volume | 105,663,236 | 28,215,427 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $489.88 |
52-Week Low | $73.75 | $298.16 |
Typical Hold Time | 63 Days | 88 Days |
Enterprise Value | $131.58B | $1.45T |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Tesla (TSLA) trades at $377.61, down 0.81% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, missing EPS estimates, while revenue has softened slightly in 2025. Analyst consensus remains positive with a $441.36 price target, and recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch.
Tesla's outlook balances innovation in autonomy and energy against near-term earnings pressure and high valuations. Investment opportunities lie in AI and robotaxi growth, but risks include intense EV competition, execution on new technologies, and profitability concerns given a P/E of 347.22. The stock's performance hinges on delivering future growth to justify its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
